Ebola Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Vaccine (cAd3-Zebov, rVSV-Zebov, TKMEbola, AVI-7537, HEB, BCRX, NNVC); Drugs (Brincidofovir, ZMapp, Favipiravir, Zoloft, Vascor); End-user (Hospitals, Ambulatory Surgery Centres, Specialized Clinics, Army Camps (Veteran Facilities))

Report Code: TIPRE00011112 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Ebola is a viral disease that can frequently cause lethal hemorrhagic fever in humans. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash, muscular pain, etc. Ebola virus causes hemorrhagic fever, which may lead to internal or external bleeding. The symptoms appear anywhere from 2 to 21 days after exposure to Ebola, though the average is 8 to 10 days.

MARKET DYNAMICS

The Ebola treatment market is driven by the increasing incidence rates of Ebola viral infection. Moreover, Due to steady government support to Ebola research, developing Ebola drugs and vaccines has also become commercially lucrative for pharmaceutical companies. This is also expected to be a major driver for the market in the coming years.

MARKET SCOPE

The "Ebola Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Ebola treatment market with detailed market segmentation by vaccine, drugs and end user. The Ebola treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Ebola treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Ebola treatment market is segmented on the basis of vaccine, drugs and end user. Based on vaccine, the market is segmented as cAd3-Zebov, rVSV-Zebov, TKMEbola. AVI-7537, HEB, BCRX and NNVC. On the basis of drugs, the market is categorized as brincidofovir, zmapp, favipiravir, zoloft and vascor . On the basis of end user, the market is categorized as hospitals, ambulatory surgery centers, specialized clinics and army camps (veteran facilities).

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Ebola treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Ebola treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Ebola treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Ebola treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Ebola treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Ebola treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for Ebola treatment in the global market. Below mentioned is the list of few companies engaged in the Ebola treatment market.

The report also includes the profiles of key players in Ebola treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.


  •   Arbutus Biopharma
  •   BioCryst Pharmaceuticals, Inc.
  •   Chimerix, Inc.
  •   GlaxoSmithKline
  •   Hemispherx Biopharma, Inc.
  •   Johnson & Johnson Services, Inc.
  •   Mapp Biopharmaceutical, Inc.
  •   NanoViricides, Inc.
  •   NewLink Genetics Corporation
  •   Sarepta Therapeutics


The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Ebola Treatment Market - By Vaccine
1.3.2 Ebola Treatment Market - By Drugs
1.3.3 Ebola Treatment Market - By End-user
1.3.4 Ebola Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. EBOLA TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. EBOLA TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. EBOLA TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. EBOLA TREATMENT - GLOBAL MARKET OVERVIEW
6.2. EBOLA TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. EBOLA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - VACCINE
7.1. OVERVIEW
7.2. VACCINE MARKET FORECASTS AND ANALYSIS
7.3. CAD3-ZEBOV
7.3.1. Overview
7.3.2. cAd3-Zebov Market Forecast and Analysis
7.4. RVSV-ZEBOV
7.4.1. Overview
7.4.2. rVSV-Zebov Market Forecast and Analysis
7.5. TKMEBOLA
7.5.1. Overview
7.5.2. TKMEbola Market Forecast and Analysis
7.6. AVI-7537
7.6.1. Overview
7.6.2. AVI-7537 Market Forecast and Analysis
7.7. HEB
7.7.1. Overview
7.7.2. HEB Market Forecast and Analysis
7.8. BCRX
7.8.1. Overview
7.8.2. BCRX Market Forecast and Analysis
7.9. NNVC
7.9.1. Overview
7.9.2. NNVC Market Forecast and Analysis
8. EBOLA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
8.1. OVERVIEW
8.2. DRUGS MARKET FORECASTS AND ANALYSIS
8.3. BRINCIDOFOVIR
8.3.1. Overview
8.3.2. Brincidofovir Market Forecast and Analysis
8.4. ZMAPP
8.4.1. Overview
8.4.2. ZMapp Market Forecast and Analysis
8.5. FAVIPIRAVIR
8.5.1. Overview
8.5.2. Favipiravir Market Forecast and Analysis
8.6. ZOLOFT
8.6.1. Overview
8.6.2. Zoloft Market Forecast and Analysis
8.7. VASCOR
8.7.1. Overview
8.7.2. Vascor Market Forecast and Analysis
9. EBOLA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - END-USER
9.1. OVERVIEW
9.2. END-USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. AMBULATORY SURGERY CENTRES
9.4.1. Overview
9.4.2. Ambulatory Surgery Centres Market Forecast and Analysis
9.5. SPECIALIZED CLINICS
9.5.1. Overview
9.5.2. Specialized Clinics Market Forecast and Analysis
9.6. ARMY CAMPS (VETERAN FACILITIES)
9.6.1. Overview
9.6.2. Army Camps (Veteran Facilities) Market Forecast and Analysis
10. EBOLA TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Ebola Treatment Market Overview
10.1.2 North America Ebola Treatment Market Forecasts and Analysis
10.1.3 North America Ebola Treatment Market Forecasts and Analysis - By Vaccine
10.1.4 North America Ebola Treatment Market Forecasts and Analysis - By Drugs
10.1.5 North America Ebola Treatment Market Forecasts and Analysis - By End-user
10.1.6 North America Ebola Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Ebola Treatment Market
10.1.6.1.1 United States Ebola Treatment Market by Vaccine
10.1.6.1.2 United States Ebola Treatment Market by Drugs
10.1.6.1.3 United States Ebola Treatment Market by End-user
10.1.6.2 Canada Ebola Treatment Market
10.1.6.2.1 Canada Ebola Treatment Market by Vaccine
10.1.6.2.2 Canada Ebola Treatment Market by Drugs
10.1.6.2.3 Canada Ebola Treatment Market by End-user
10.1.6.3 Mexico Ebola Treatment Market
10.1.6.3.1 Mexico Ebola Treatment Market by Vaccine
10.1.6.3.2 Mexico Ebola Treatment Market by Drugs
10.1.6.3.3 Mexico Ebola Treatment Market by End-user
10.2. EUROPE
10.2.1 Europe Ebola Treatment Market Overview
10.2.2 Europe Ebola Treatment Market Forecasts and Analysis
10.2.3 Europe Ebola Treatment Market Forecasts and Analysis - By Vaccine
10.2.4 Europe Ebola Treatment Market Forecasts and Analysis - By Drugs
10.2.5 Europe Ebola Treatment Market Forecasts and Analysis - By End-user
10.2.6 Europe Ebola Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Ebola Treatment Market
10.2.6.1.1 Germany Ebola Treatment Market by Vaccine
10.2.6.1.2 Germany Ebola Treatment Market by Drugs
10.2.6.1.3 Germany Ebola Treatment Market by End-user
10.2.6.2 France Ebola Treatment Market
10.2.6.2.1 France Ebola Treatment Market by Vaccine
10.2.6.2.2 France Ebola Treatment Market by Drugs
10.2.6.2.3 France Ebola Treatment Market by End-user
10.2.6.3 Italy Ebola Treatment Market
10.2.6.3.1 Italy Ebola Treatment Market by Vaccine
10.2.6.3.2 Italy Ebola Treatment Market by Drugs
10.2.6.3.3 Italy Ebola Treatment Market by End-user
10.2.6.4 Spain Ebola Treatment Market
10.2.6.4.1 Spain Ebola Treatment Market by Vaccine
10.2.6.4.2 Spain Ebola Treatment Market by Drugs
10.2.6.4.3 Spain Ebola Treatment Market by End-user
10.2.6.5 United Kingdom Ebola Treatment Market
10.2.6.5.1 United Kingdom Ebola Treatment Market by Vaccine
10.2.6.5.2 United Kingdom Ebola Treatment Market by Drugs
10.2.6.5.3 United Kingdom Ebola Treatment Market by End-user
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Ebola Treatment Market Overview
10.3.2 Asia-Pacific Ebola Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Ebola Treatment Market Forecasts and Analysis - By Vaccine
10.3.4 Asia-Pacific Ebola Treatment Market Forecasts and Analysis - By Drugs
10.3.5 Asia-Pacific Ebola Treatment Market Forecasts and Analysis - By End-user
10.3.6 Asia-Pacific Ebola Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Ebola Treatment Market
10.3.6.1.1 Australia Ebola Treatment Market by Vaccine
10.3.6.1.2 Australia Ebola Treatment Market by Drugs
10.3.6.1.3 Australia Ebola Treatment Market by End-user
10.3.6.2 China Ebola Treatment Market
10.3.6.2.1 China Ebola Treatment Market by Vaccine
10.3.6.2.2 China Ebola Treatment Market by Drugs
10.3.6.2.3 China Ebola Treatment Market by End-user
10.3.6.3 India Ebola Treatment Market
10.3.6.3.1 India Ebola Treatment Market by Vaccine
10.3.6.3.2 India Ebola Treatment Market by Drugs
10.3.6.3.3 India Ebola Treatment Market by End-user
10.3.6.4 Japan Ebola Treatment Market
10.3.6.4.1 Japan Ebola Treatment Market by Vaccine
10.3.6.4.2 Japan Ebola Treatment Market by Drugs
10.3.6.4.3 Japan Ebola Treatment Market by End-user
10.3.6.5 South Korea Ebola Treatment Market
10.3.6.5.1 South Korea Ebola Treatment Market by Vaccine
10.3.6.5.2 South Korea Ebola Treatment Market by Drugs
10.3.6.5.3 South Korea Ebola Treatment Market by End-user
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Ebola Treatment Market Overview
10.4.2 Middle East and Africa Ebola Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Ebola Treatment Market Forecasts and Analysis - By Vaccine
10.4.4 Middle East and Africa Ebola Treatment Market Forecasts and Analysis - By Drugs
10.4.5 Middle East and Africa Ebola Treatment Market Forecasts and Analysis - By End-user
10.4.6 Middle East and Africa Ebola Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Ebola Treatment Market
10.4.6.1.1 South Africa Ebola Treatment Market by Vaccine
10.4.6.1.2 South Africa Ebola Treatment Market by Drugs
10.4.6.1.3 South Africa Ebola Treatment Market by End-user
10.4.6.2 Saudi Arabia Ebola Treatment Market
10.4.6.2.1 Saudi Arabia Ebola Treatment Market by Vaccine
10.4.6.2.2 Saudi Arabia Ebola Treatment Market by Drugs
10.4.6.2.3 Saudi Arabia Ebola Treatment Market by End-user
10.4.6.3 U.A.E Ebola Treatment Market
10.4.6.3.1 U.A.E Ebola Treatment Market by Vaccine
10.4.6.3.2 U.A.E Ebola Treatment Market by Drugs
10.4.6.3.3 U.A.E Ebola Treatment Market by End-user
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Ebola Treatment Market Overview
10.5.2 South and Central America Ebola Treatment Market Forecasts and Analysis
10.5.3 South and Central America Ebola Treatment Market Forecasts and Analysis - By Vaccine
10.5.4 South and Central America Ebola Treatment Market Forecasts and Analysis - By Drugs
10.5.5 South and Central America Ebola Treatment Market Forecasts and Analysis - By End-user
10.5.6 South and Central America Ebola Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Ebola Treatment Market
10.5.6.1.1 Brazil Ebola Treatment Market by Vaccine
10.5.6.1.2 Brazil Ebola Treatment Market by Drugs
10.5.6.1.3 Brazil Ebola Treatment Market by End-user
10.5.6.2 Argentina Ebola Treatment Market
10.5.6.2.1 Argentina Ebola Treatment Market by Vaccine
10.5.6.2.2 Argentina Ebola Treatment Market by Drugs
10.5.6.2.3 Argentina Ebola Treatment Market by End-user
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL EBOLA TREATMENT MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. EBOLA TREATMENT MARKET, KEY COMPANY PROFILES
13.1. ARBUTUS BIOPHARMA
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BIOCRYST PHARMACEUTICALS, INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. CHIMERIX, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. HEMISPHERX BIOPHARMA, INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. JOHNSON AND JOHNSON SERVICES, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. MAPP BIOPHARMACEUTICAL, INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. NANOVIRICIDES, INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. NEWLINK GENETICS CORPORATION
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. SAREPTA THERAPEUTICS
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Arbutus Biopharma
2. BioCryst Pharmaceuticals, Inc.
3. Chimerix, Inc.
4. GlaxoSmithKline
5. Hemispherx Biopharma, Inc.
6. Johnson & Johnson Services, Inc.
7. Mapp Biopharmaceutical, Inc.
8. NanoViricides, Inc.
9. NewLink Genetics Corporation
10. Sarepta Therapeutics
TIPRE00011112
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking